PULSE BIOSCIENCES INC
PLSENASDAQ🏆 #1273 by market capEarnings Nov 3US Equity
$44.33▲ $3.10 (+6.99%)
Live1h—
24h▲ 7.0%
7d▲ 16.9%
14d▲ 24.9%
30d▲ 68.9%
1y▲ 198.3%
🏦Market Cap
$3.07B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
-21.0%
Thin
💵FCF Margin
—
⚖️P/S Ratio
3940.8x
Expensive
Otter Score
50
Weak
Trading Snapshot
- Day Range
- $43.84 – $45.04
- 52-Week Range
- $12.56 – $45.90
- Volume
- $6.10B
- Avg Volume
- $6.92B
- Shares Outstanding
- 69.2M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $751,271
- Last Q Revenue
- $201,776
- P/E Ratio
- —
- P/S Ratio
- 3940.8x
- EPS (TTM)
- $-1.10
- Dividend Yield
- —
Why Investors Own PLSE
- ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$751,271▲ +19.5% YoY
Gross Margin (TTM)
77.8%▲ +2.5% YoY
Operating Income (TTM)
$151,757▲ +19.5% YoY
Free Cash Flow (TTM)
$157,767▲ +19.5% YoY
About PULSE BIOSCIENCES INC
A company profile for PULSE BIOSCIENCES INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
50/100
Analyst Ratings
ⓘConsensus
Buy
9 analysts
Strong Buy3
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026
Latest News & Updates
🚀
Benzinga·1d ago
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $43
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $32 to $43.
SeekingAlpha·4d ago
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsPhilip Taylor - AssociatePaul LaViolette - President, CEO...
🌌
Benzinga·5d ago
Pulse Biosciences Q2 EPS $(0.36), Inline, Sales $434.000K Miss $533.333K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 28.57 percent decrease over losses of $(0.28) per share from the same period last year.